MINORITY/UNDERSERVED NCI COMMUNITY ONCOLOGY RESEARCH PROGRAM

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Target: n/a Total: 2374

SPECIMEN COLLECTION  AUGUSTA UNIVERSITY
Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Prostate, Colorectal, Liver, Kidney, and Multiple Myeloma among Racially and Ethnically Diverse Populations

AUGUSTA UNIVERSITY
Patient-derived Models Tissue Procurement Protocol for the National Cancer Institute

MOLECULAR ANALYSIS FOR THERAPY CHOICE (MATCH)

BREAST PROTOCOLS OPEN TO ENROLLMENT

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
Target: 317 Total: 221

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
Alternate Approaches for Clinical Stage II and III Estrogen Receptor Positive Breast Cancer NeoAdjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Target: 1475 Total: 1113

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

ATHENS & DEKALB MEDICAL
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer 

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial 

ATHENS & DEKALB MEDICAL
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy 

ATHENS & DEKALB MEDICAL
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

ATHENS, DEKALB MEDICAL & PHOEBE CANCER CENTER
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy. 

AUGUSTA UNIVERSITY, ATHENS, DEKALB MEDICAL & PHOEBE CANCER CENTER
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
Target: 1000 Total: 171

GYNECOLOGICAL PROTOCOLS OPEN TO ENROLLMENT

AUGUSTA UNIVERSITY
A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

Target: 210 Total: 132

AUGUSTA UNIVERSITY
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary.

Target: 128 Total: 49

AUGUSTA UNIVERSITY
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva

Target: 52 Total: 36

AUGUSTA UNIVERSITY & DEKALB MEDICAL
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial.

Target: 285 Total: 171

AUGUSTA UNIVERSITY
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Target: 188 Total: 97

AUGUSTA UNIVERSITY
A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Target: 147 Total: 17

AUGUSTA UNIVERSITY & DEKALB MEDICAL
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

Target: 488 Total: 32

GYNECOLOGICAL PENDING PROTOCOLS

GYNECOLOGICL PREVENTION PROTOCOLS OPEN TO ENROLLMENT

AUGUSTA UNIVERSITY, DEKALB MEDICAL & MOOREHOUSE
Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?”

Target: 1150 Total: 1129

AUGUSTA UNIVERSITY, ATHENS & DEKALB MEDICAL
(EROS) Engendering Reproductive Health within Oncologic Survivorship

Target: 612 Total: 179

BRAIN

HEAD AND NECK PROTOCOL OPEN TO ENROLLMENT

ADULT LEUKEMIA PENDING PROTOCOLS

ADULT LEUKEMIA PROTOCOLS OPEN TO ENROLLMENT

LYMPHOMA PROTOCOLS OPEN TO ENROLLMENT

LUNG PROTOCOLS OPEN TO ENROLLMENT

AUGUSTA UNIVERSITY, ATHENS, DEKALB MEDICAL & 

PHOEBE CANCER CENTER

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Target: 10000 Total: 1592

ALCHEMIST

AUGUSTA UNIVERSITY, ATHENS, DEKALB MEDICAL & PHOEBE CANCER CENTER 

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Target: 8300 Total: 3046

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) 
Target: 450 Total: 194

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein 
Target: 378 Total: 61

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Target: 714 Total: 338

PENDING LUNG PROTOCOLS

OPEN MELANOMA PROTOCOLS

GASTROINTESTINAL

PREVENTION PROTOCOL OPEN TO ENROLLMENT

AUGUSTA UNIVERSITY
The Caucasian/other races cohort is closed to accrual

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Target: 1000 Total: 1006

CCDR PROTOCOLS

CCDR PROTOCOLS PENDING

PEDIATRIC PROTOCOLS OPEN TO ENROLLMENT (AU)

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Target: 17230 Total: 16078

Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Target: 5872 Total: 8906 

Temporarily Closed
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
Target: 5437 Total: 5031

Temporarily Closed
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) 
Target: 1400 Total: 832

Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years: A Groupwide Phase III Study
Target: 400 Total: 399

Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Target: 330 Total: 189

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults

Key Adverse Events After Childhood Cancer
Target: 8100 Total: 3482  

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy
Target: 621 Total: 198

Neuroblastoma Biology Studies
Target: 10,000 Total: 9869

Renal Tumors Classification, Biology and Banking Study
Banking 
Total: 5987

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib
Target: 340 Total: 115